Pacific Biosciences of California

PacBio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. We provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. Our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. With a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.

Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2004
Size (employees)
438 (est)
Website
pacb.com
Pacific Biosciences of California was founded in 2004 and is headquartered in Menlo Park, US

Pacific Biosciences of California Office Locations

Pacific Biosciences of California has an office in Menlo Park
Menlo Park, US (HQ)
1380 Willow Rd

Pacific Biosciences of California Data and Metrics

Pacific Biosciences of California Financial Metrics

Pacific Biosciences of California's revenue was reported to be $24.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

24.9 m

Gross profit (Q1, 2017)

8.9 m

Gross profit margin (Q1, 2017), %

36%

Net income (Q1, 2017)

(23.9 m)

EBIT (Q1, 2017)

(23.3 m)

Market capitalization (22-Aug-2017)

407 m

Cash (31-Mar-2017)

29 m
Pacific Biosciences of California's current market capitalization is $407 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

28.2 m60.6 m92.8 m90.7 m

Revenue growth, %

115%53%(2%)

Cost of goods sold

21.8 m37.2 m39.3 m46.6 m

Gross profit

6.4 m23.4 m53.5 m44.2 m

Gross profit Margin, %

23%39%58%49%

R&D expense

67.6 m

Operating expense total

67.6 m

EBIT

(77.5 m)(62.9 m)(29.1 m)(71.2 m)

EBIT margin, %

(275%)(104%)(31%)(79%)

Interest expense

2.5 m2.8 m2.9 m3.2 m

Net Income

(79.3 m)(66.2 m)(31.7 m)(74.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

11.4 m20.6 m17.6 m24.9 m13.9 m19.1 m20.7 m25.1 m24.9 m

Cost of goods sold

8.3 m7.5 m11.7 m10.4 m7.4 m9.6 m10.1 m12.5 m16 m

Gross profit

3.1 m13.2 m5.9 m14.5 m6.6 m9.5 m10.6 m12.6 m8.9 m

Gross profit Margin, %

27%64%34%58%47%50%51%50%36%

R&D expense

12.4 m11.7 m14.5 m15 m16.2 m16.4 m17.5 m17.5 m17 m

Operating expense total

12.4 m11.7 m14.5 m15 m16.2 m16.4 m17.5 m17.5 m17 m

EBIT

(18.3 m)(8.4 m)(19.3 m)(11.4 m)(18.6 m)(18.1 m)(16.7 m)(23.3 m)

EBIT margin, %

(160%)(41%)(110%)(46%)(97%)(87%)(67%)(94%)

Interest expense

701 k716 k697 k715 k741 k779 k795 k821 k838 k

Net Income

(19.1 m)(9.2 m)(20.2 m)(11.9 m)1.8 m(19.4 m)(18.5 m)(17.5 m)(23.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

26.4 m36.4 m33.6 m16.8 m

Accounts Receivable

2.7 m3.4 m5.2 m11.4 m

Inventories

1.1 m1.7 m12.1 m15.6 m

Current Assets

126.5 m117.8 m110.5 m109 m

PP&E

9.2 m6.6 m8.5 m14.6 m

Total Assets

136.2 m124.5 m131.1 m137.9 m

Accounts Payable

1.7 m5.6 m4.7 m8.4 m

Total Debt

28.2 m29.9 m32.2 m

Current Liabilities

22.6 m31.5 m38.2 m33.8 m

Total Liabilities

53.2 m

Additional Paid-in Capital

684.4 m736.3 m786.6 m872.1 m

Retained Earnings

(615.3 m)(681.5 m)(713.2 m)(787.5 m)

Total Equity

69.2 m54.9 m73.5 m84.7 m

Debt to Equity Ratio

0.5 x0.4 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x

Financial Leverage

2 x2.3 x1.8 x1.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

28.2 m35.4 m30.3 m25.9 m27.2 m20.1 m24.8 m22.8 m29 m

Accounts Receivable

4.3 m2.4 m5.3 m4 m4.2 m8 m10.4 m11.8 m10.4 m

Inventories

9.4 m11.4 m13.5 m12 m11.6 m12.2 m14.2 m16.5 m15.3 m

Current Assets

119.9 m114.1 m99.5 m90.2 m86.2 m119.1 m138.1 m122.5 m88.3 m

PP&E

7.9 m7 m6.7 m6.4 m7.9 m9.1 m11.2 m14 m42.4 m

Total Assets

128.2 m121.6 m106.4 m96.8 m99.8 m140.2 m161.4 m150.6 m135.5 m

Accounts Payable

5.4 m5.8 m6.9 m5.8 m6.1 m4.7 m5.4 m8.3 m8.2 m

Current Liabilities

28 m29.1 m38.4 m39 m38.8 m32 m33.8 m32.1 m35.4 m

Additional Paid-in Capital

712.2 m715.4 m742 m747.3 m753 m821.2 m858.9 m867.1 m880.5 m

Retained Earnings

(653.3 m)(662.5 m)(701.6 m)(713.6 m)(711.8 m)(732.5 m)(751 m)(768.5 m)(811.4 m)

Total Equity

59 m53 m40.5 m33.8 m41.4 m88.8 m108.1 m98.7 m69.2 m

Financial Leverage

2.2 x2.3 x2.6 x2.9 x2.4 x1.6 x1.5 x1.5 x2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(79.3 m)(66.2 m)(31.7 m)(74.4 m)

Depreciation and Amortization

5.6 m4.2 m3.7 m3.9 m

Accounts Receivable

76 k(660 k)(1.7 m)(6.2 m)

Inventories

(60 k)(1.3 m)(2.5 m)(6.2 m)

Accounts Payable

(1.3 m)3.9 m(716 k)3.4 m

Cash From Operating Activities

(29.8 m)(51.5 m)(47.9 m)(67.9 m)

Purchases of PP&E

(909 k)(1.6 m)(3 m)(8.2 m)

Cash From Investing Activities

(33.1 m)19.6 m8.6 m(14.9 m)

Cash From Financing Activities

42.8 m42 m36.5 m65.9 m

Interest Paid

1.2 m1.8 m1.8 m1.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(19.1 m)(9.2 m)(20.2 m)(11.9 m)1.8 m(19.4 m)(18.5 m)(17.5 m)(23.9 m)

Accounts Receivable

4.3 m2.4 m5.3 m4 m4.2 m8 m10.4 m11.8 m10.4 m

Inventories

13.5 m12 m11.6 m12.2 m14.2 m16.5 m15.3 m

Accounts Payable

5.4 m5.8 m6.9 m5.8 m6.1 m4.7 m5.4 m8.3 m8.2 m
USDY, 2017

Revenue/Employee

56.9 k

Financial Leverage

2 x

Pacific Biosciences of California Operating Metrics

FY, 2016

Patents (US)

221

Patents Pending

187

Patents (foreign)

133

Pacific Biosciences of California Market Value History

Pacific Biosciences of California Revenue Breakdown

Pacific Biosciences of California Median Salaries

Source: 25 public H-1B filings from Pacific Biosciences of California

Traffic Overview of Pacific Biosciences of California

Pacific Biosciences of California Online and Social Media Presence

Pacific Biosciences of California Company Life and Culture

You may also be interested in